The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease

Journal of Cystic Fibrosis

Volumn 10, Issue SUPPL. 2, 2011, Pages

  Zhou, Zhe ^a   Duerr, Julia ^a   Johannesson, Bjarki ^a,b   Schubert, Susanne C ^a,b   Treis, Diana ^a   Harm, Maria ^a   Graeber, Simon Y ^a   Dalpke, Alexander ^a   Schultz, Carsten ^b   Mall, Marcus A ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

Airway inflammation; Airway surface liquid; Cystic fibrosis; ENaC; Mouse model; Mucus obstruction

Indexed keywords

ALLERGEN; ALPHA EPITHELIAL SODIUM CHANNEL; AMILORIDE; ANTIINFLAMMATORY AGENT; BETA EPITHELIAL SODIUM CHANNEL; CHEMOKINE RECEPTOR CXCR1; CLARA CELL PROTEIN; CXCL3 CHEMOKINE; DEOXYRIBONUCLEASE; EOTAXIN; EPITHELIAL SODIUM CHANNEL; GAMMA EPITHELIAL SODIUM CHANNEL; INTERLEUKIN 13; MUCIN; SODIUM CHANNEL; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACIDIFICATION; AIRWAY; AIRWAY OBSTRUCTION; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; ASPHYXIA; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM; CHRONIC INFLAMMATION; CHRONIC LUNG DISEASE; CLARA CELL; COAGULASE NEGATIVE STAPHYLOCOCCUS; CYSTIC FIBROSIS; CYSTIC FIBROSIS LUNG DISEASE; DEFENSE MECHANISM; DISEASE SEVERITY; DRUG EFFICACY; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; GENE OVEREXPRESSION; GENOTYPE; HAEMOPHILUS INFLUENZAE; HYPERTENSION; IMMUNE DYSREGULATION; LACTOBACILLUS; LUNG; LUNG CLEARANCE; LUNG DISEASE; LUNG FUNCTION; LUNG LAVAGE; MACROPHAGE; METAPLASIA; MICROCOCCUS; MORTALITY; MUCOCILIARY CLEARANCE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RESPIRATORY DISTRESS; RESPIRATORY TRACT INFECTION; SODIUM ABSORPTION; SODIUM TRANSPORT; TRANSGENIC MOUSE; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; EPITHELIAL SODIUM CHANNEL; HUMANS; LUNG; MICE; MICE, TRANSGENIC;

EID: 79958142002     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/S1569-1993(11)60021-0     Document Type: Article

References (68)

1. Mall M, Boucher RC Pathogenesis of pulmonary disease in cystic fibrosis. Cystic fibrosis in the 21st century 2006, 116-121. Karger, Basel. A. Bush, E. Alton, J. Davies, U. Griesenbach, A. Jaffe (Eds.).
2. Zuelzer WW, Newton WA The pathogenesis of fibrocystic disease of the pancreas; a study of 36 cases with special reference to the pulmonary lesions. Pediatrics 1949, 4:53-69.
3. Sly PD, Brennan S, Gangell C, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009, 180:146-152.
4. Snouwaert JN, Brigman KK, Latour AM, et al. An animal model for cystic fibrosis made by gene targeting. Science 1992, 257:1083-1088.
5. Colledge WH, Abella BS, Southern KW, et al. Generation and characterization of a ΔF508 cystic fibrosis mouse model. Nat Genet 1995, 10:445-452.
6. Grubb BR, Boucher RC Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiol Rev 1999, 79:S 193-S 214.
7. Wilke M, Buijs-Offerman RM, Aarbiou J, et al. Mouse models of cystic fibrosis: Phenotypic analysis and research applications. J Cyst Fibros 2011, 10(Suppl 2):152-171.
8. Kent G, Iles R, Bear CE, et al. Lung disease in mice with cystic fibrosis. J Clin Invest 1997, 100:3060-3069.
9. Durie PR, Kent G, Phillips MJ, Ackerley CA Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am J Pathol 2004, 164:1481-1493.
10. Grubb BR, Paradiso AM, Boucher RC Anomalies in ion transport in CF mouse trachéal epithelium. Am J Physiol 1994, 267:C293-C300.
11. Grubb BR, Jones JH, Boucher RC Mucociliary transport determined by in vivo microdialysis in the airways of normal and CF mice. Am J Physiol Lung Cell Mol Physiol 2004, 286:L588-L595.
12. Knowles MR, Stutts MJ, Spock A, Fischer N, Gatzy JT, Boucher RC Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science 1983, 221:1067-1070.
13. Verkman AS, Song Y, Thiagarajah JR Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease. Am J Physiol Cell Physiol 2003, 284:C2-15.
14. Trout L, King M, Feng W, Inglis SK, Ballard ST Inhibition of airway liquid secretion and its effect on the physical properties of airway mucus. Am J Physiol 1998, 274:L258-L263.
15. +] and pH but elevated viscosity. Proc Nati Acad Sci USA 2001, 98:8119-8123.
16. Regnis JA, Robinson M, Bailey DL, et al. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am J Respir Crit Care Med 1994, 150:66-71.
17. Mall MA Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models. J Aerosol Med Pulm Drug Deliv 2008, 21:13-24.
18. - secretion in nasal epithelia of CF mice. Am J Physiol 1994, 266:C1478-C1483.
19. (-/-) mice. Proc Nati Acad Sci U S A 1994, 91:479-483.
20. + transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. J Clin Invest 1986, 78:1245-1252.
21. Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995, 269:847-850.
22. + conductance when coexpressed in Xenopus oocytes. FEBS Lett 1996, 381:47-52.
23. + conductance is reduced by CFTR in normal but not in cystic fibrosis airways. J Clin Invest 1998, 102:15-21.
24. + channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease. Exp Physiol 2009, 94:171-174.
25. Schild L, Canessa CM, Shimkets RA, Gautschi I, Lifton RP, Rossier BC A mutation in the epithelial sodium channel causing Liddle disease increases channel activity in the Xenopus laevis oocyte expression system. Proc Nati Acad Sci U S A 1995, 92:5699-5703.
26. Hackett BP, Gitlin JD Cell-specific expression of a Clara cell secretory protein-human growth hormone gene in the bronchiolar epithelium of transgenic mice. Proc Nati Acad Sci U S A 1992, 89:9079-9083.
27. Pack RJ, Al Ugaily LH, Morris G The cells of the tracheobronchial epithelium of the mouse: a quantitative light and electron microscope study. J Anat 1981, 132:71-84.
28. + channel is made of three homologous subunits. Nature 1994, 367:463-467.
29. Ahn YJ, Brooker DR, Kosari F, et al. Cloning and functional expression of the mouse epithelial sodium channel. Am J Physiol 1999, 277:F121-F129.
30. + absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004, 10:487-493.
31. Fyfe GK, Canessa CM Subunit composition determines the single channel kinetics of the epithelial sodium channel. J Gen Physiol 1998, 112:423-432.
32. Mall MA, Button B, Johannesson B, et al. Airway surface liquid volume regulation determines different airway phenotypes in liddle compared with βENaC-overexpressing mice. J Biol Chem 2010, 285:26945-26955.
33. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998, 95:1005-1015.
34. Wine JJ The genesis of cystic fibrosis lung disease. J Clin Invest 1999, 103:309-312.
35. Sims DE, Horne MM Heterogeneity of the composition and thickness of trachéal mucus in rats. Am J Physiol 1997, 273:L1036-L1041.
36. Matthews LM, Spector S, Lemm J, Potter JL Studies on pulmonary secretions. Am Rev Respir Dis 1963, 88:199-204.
37. + channel-overexpressing mice. Am J Respir Crit Care Med 2008, 177:730-742.
38. + channel-overexpressing mice: role of TNF-a and IL-4Ra signaling, influence of neonatal development, and limited efficacy of glucocorticoid treatment. J Immunol 2009, 182:4357-4367.
39. Evans CM, Koo JS Airway mucus: the good, the bad, the sticky. Pharmacol Ther 2009, 121:332-348.
40. Fujii T, Hayashi S, Hogg JC, Vincent R, Van Eeden SF Particulate matter induces cytokine expression in human bronchial epithelial cells. Am J Respir Cell Mol Biol 2001, 25:265-271.
41. Voynow JA, Young LR, Wang Y, Horger T, Rose MC, Fischer BM Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. Am J Physiol 1999, 276:L835-L843.
42. Nakamura H, Yoshimura K, McElvaney NG, Crystal RG Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 1992, 89:1478-1484.
43. Takeyama K, Dabbagh K, Lee HM, et al. Epidermal growth factor system regulates mucin production in airways. Proc Nati Acad Sci U S A 1999, 96:3081-3086.
44. Adkins B, Leclerc C, Marshall-Clarke S Neonatal adaptive immunity comes of age. Nat Rev Immunol 2004, 4:553-564.
45. Knowles MR, Boucher RC Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002, 109:571-577.
46. Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002, 109:317-325.
47. Hartl D, Latzin P, Hordijk P, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007, 13:1423-1430.
48. Nonnenmacher C, Dalpke A, Rochon J, Flores-de-Jacoby L, Mutters R, Heeg K Real-time polymerase chain reaction for detection and quantification of bacteria in periodontal patients. J Periodontol 2005, 76:1542-1549.
49. Pier GB, Grout M, Zaidi TS Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Nati Acad Sci USA 1997, 94:12088-12093.
50. Di A, Brown ME, Deriy LV, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 2006, 8:933-944.
51. Teichgraber V, Ulrich M, Endlich N, et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008, 14:382-391.
52. Drumm ML, Konstan MW, Schluchter MD, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005, 353:1443-1453.
53. O'Neal WK, Livraghi A, Threadgill DW, et al. Assessment of genetic modifiers for phenotypic severity of βENaC transgenic mice. Ped.Pulmonol.Supp.30 [A184], 266. 2007.
54. Peters LL, Robledo RF, Bult CJ, Churchill GA, Paigen BJ, Svenson KL The mouse as a model for human biology: a resource guide for complex trait analysis. Nat Rev Genet 2007, 8:58-69.
55. Zhou Z, Treis D, Schubert SC, et al. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in βENaC-overexpressing mice. Am J Respir Crit Care Med 2008, 178:1245-1256.
56. Mehta A A global perspective on newborn screening for cystic fibrosis. Curr Opin Pulm Med 2007, 13:510-514.
57. Graham A, Hasani A, Alton EW, et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993, 6:1243-1248.
58. Pons G, Marchand MC, d'Athis P, et al. French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Amiloride-AFLM Collaborative Study Group. Pediatr Pulmonol 2000, 30:25-31.
59. Noone PG, Regnis JA, Liu X, et al. Airway deposition and clearance and systemic pharmacokinetics of amiloride following aerosolization with an ultrasonic nebulizer to normal airways. Chest 1997, 112:1283-1290.
60. Hofmann T, Stutts MJ, Ziersch A, et al. Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis. Am J Respir Crit Care Med 1998, 157:1844-1849.
61. Kim EY, Battaile JT, Patel AC, et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med 2008, 14:633-640.
62. Hirsh AJ, Molino BF, Zhang J, et al. Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis. J Med Chem 2006, 49:4098-4115.
63. Hirsh AJ, Zang J, Zamurs A, et al. Pharmacological properties of 552-02, a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis Lung Disease. J Pharmacol Exp Ther 2008, 325:77-88.
64. Becq F, Mall MA, Sheppard DN, Conese M, Zegarra-Moran O Pharmacological therapy for cystic fibrosis: From bench to bedside. J Cyst Fibros 2011, 10(Suppl 2):129-145.
65. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994, 331:637-642.
66. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006, 354:229-240.
67. Frizzell RA, Pilewski JM Finally, mice with CF lung disease. Nat Med 2004, 10:452-454.
68. Gentzsch M, Choudhury A, Chang XB, Pagano RE, Riordan JR Msassembled mutant ΔF508 CFTR in the distal secretory pathway alters cellular lipid trafficking. J Cell Sci 2007, 120:447-455.